{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Paralysie pseudobulbaire : Questions médicales les plus fréquentes",
"headline": "Paralysie pseudobulbaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Paralysie pseudobulbaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-02",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Paralysie pseudobulbaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Paralysie",
"url": "https://questionsmedicales.fr/mesh/D010243",
"about": {
"@type": "MedicalCondition",
"name": "Paralysie",
"code": {
"@type": "MedicalCode",
"code": "D010243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.592.636"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Paralysie pseudobulbaire",
"alternateName": "Pseudobulbar Palsy",
"code": {
"@type": "MedicalCode",
"code": "D020828",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kenjiro Kunieda",
"url": "https://questionsmedicales.fr/author/Kenjiro%20Kunieda",
"affiliation": {
"@type": "Organization",
"name": "Neurology, Gifu University Graduate School of Medicine, Gifu, JPN."
}
},
{
"@type": "Person",
"name": "Tomohisa Ohno",
"url": "https://questionsmedicales.fr/author/Tomohisa%20Ohno",
"affiliation": {
"@type": "Organization",
"name": "Dentistry, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN."
}
},
{
"@type": "Person",
"name": "Ichiro Fujishima",
"url": "https://questionsmedicales.fr/author/Ichiro%20Fujishima",
"affiliation": {
"@type": "Organization",
"name": "Rehabilitation Medicine, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN."
}
},
{
"@type": "Person",
"name": "Victor Kekere",
"url": "https://questionsmedicales.fr/author/Victor%20Kekere",
"affiliation": {
"@type": "Organization",
"name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA."
}
},
{
"@type": "Person",
"name": "Patrice Fouron",
"url": "https://questionsmedicales.fr/author/Patrice%20Fouron",
"affiliation": {
"@type": "Organization",
"name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Ocular changes of non-segmental vitiligo: A case-control study.",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/35971248",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ajd.13909"
}
},
{
"@type": "ScholarlyArticle",
"name": "Autoimmune atrophic gastritis and coeliac disease: A case-control study.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35906165",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.dld.2022.07.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Recruiting controls from an online panel for a case-control study enabled a timely and reliable foodborne",
"datePublished": "2023-04-05",
"url": "https://questionsmedicales.fr/article/37017135",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1017/S0950268823000493"
}
},
{
"@type": "ScholarlyArticle",
"name": "A robust approach for electronic health record-based case-control studies with contaminated case pools.",
"datePublished": "2022-07-22",
"url": "https://questionsmedicales.fr/article/35841231",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/biom.13721"
}
},
{
"@type": "ScholarlyArticle",
"name": "New weighting methods when cases are only a subset of events in a nested case-control study.",
"datePublished": "2022-06-26",
"url": "https://questionsmedicales.fr/article/35754309",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/bimj.202100194"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Manifestations neurologiques",
"item": "https://questionsmedicales.fr/mesh/D009461"
},
{
"@type": "ListItem",
"position": 5,
"name": "Paralysie",
"item": "https://questionsmedicales.fr/mesh/D010243"
},
{
"@type": "ListItem",
"position": 6,
"name": "Paralysie pseudobulbaire",
"item": "https://questionsmedicales.fr/mesh/D020828"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Paralysie pseudobulbaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Paralysie pseudobulbaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Paralysie pseudobulbaire",
"description": "Comment diagnostique-t-on la paralysie pseudobulbaire ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels symptômes aident au diagnostic ?\nLa paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?\nPeut-on confondre cette paralysie avec d'autres troubles ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=8#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Paralysie pseudobulbaire",
"description": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?\nLa difficulté à parler est-elle un symptôme courant ?\nLes patients ressentent-ils de la douleur ?\nY a-t-il des variations dans les symptômes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=8#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Paralysie pseudobulbaire",
"description": "Peut-on prévenir la paralysie pseudobulbaire ?\nComment réduire le risque de paralysie pseudobulbaire ?\nLes AVC peuvent-ils être prévenus ?\nLa réhabilitation précoce aide-t-elle à prévenir la paralysie ?\nLes habitudes alimentaires influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=8#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Paralysie pseudobulbaire",
"description": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?\nLa rééducation est-elle utile ?\nLes médicaments peuvent-ils réduire les symptômes ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements sont-ils efficaces pour tous les patients ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=8#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Paralysie pseudobulbaire",
"description": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?\nLa dépression est-elle une complication fréquente ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des risques d'isolement social ?\nLes complications peuvent-elles être traitées ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=8#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Paralysie pseudobulbaire",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de paralysie pseudobulbaire ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie peut-il influencer le risque ?\nLes maladies cardiovasculaires sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Case-Control+Studies&page=8#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la paralysie pseudobulbaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et l'évaluation des symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie cérébrale comme l'IRM peuvent être utilisés pour identifier les lésions."
}
},
{
"@type": "Question",
"name": "Quels symptômes aident au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des accès de rire ou de pleurs inappropriés et des troubles de la parole."
}
},
{
"@type": "Question",
"name": "La paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est souvent associée à des maladies neurologiques comme la sclérose en plaques ou les AVC."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette paralysie avec d'autres troubles ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres troubles affectant le contrôle émotionnel et moteur."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux symptômes incluent des crises de rire ou de pleurs incontrôlables."
}
},
{
"@type": "Question",
"name": "La difficulté à parler est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent éprouver des difficultés à articuler et à contrôler leur voix."
}
},
{
"@type": "Question",
"name": "Les patients ressentent-ils de la douleur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La paralysie pseudobulbaire ne cause généralement pas de douleur physique, mais des malaises émotionnels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des variations dans les symptômes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en intensité et en fréquence d'un patient à l'autre."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, les symptômes peuvent s'aggraver et affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la paralysie pseudobulbaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais la gestion des maladies sous-jacentes peut aider."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de paralysie pseudobulbaire ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain et traiter les affections neurologiques peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les AVC peuvent-ils être prévenus ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en contrôlant les facteurs de risque comme l'hypertension et le diabète, on peut réduire les AVC."
}
},
{
"@type": "Question",
"name": "La réhabilitation précoce aide-t-elle à prévenir la paralysie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une réhabilitation précoce après un AVC ou une lésion cérébrale peut aider à prévenir la paralysie."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut contribuer à la santé neurologique et réduire les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments comme les antidépresseurs et la thérapie comportementale."
}
},
{
"@type": "Question",
"name": "La rééducation est-elle utile ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la rééducation orthophonique peut aider à améliorer les capacités de communication."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils réduire les symptômes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent réduire la fréquence et l'intensité des épisodes émotionnels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches comme la thérapie psychologique peuvent également être bénéfiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces pour tous les patients ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements peut varier selon les individus et la gravité des symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles de la déglutition et des problèmes de communication."
}
},
{
"@type": "Question",
"name": "La dépression est-elle une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent développer une dépression en raison de l'impact émotionnel de la maladie."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'isolement social ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les difficultés de communication peuvent entraîner un isolement social pour les patients."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être traitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées avec des traitements appropriés et un soutien."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les AVC, les maladies neurodégénératives et les traumatismes crâniens sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de paralysie pseudobulbaire ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout chez les personnes âgées ayant des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il influencer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies cardiovasculaires augmentent le risque de paralysie pseudobulbaire par AVC."
}
}
]
}
]
}
Vitiligo is a skin disorder in which the melanocytes are destroyed. Melanocytes can be destroyed anywhere in the body, compromising the function of the organs where they are found. Melanocytes in the ...
This study included 40 non-segmental vitiligo patients and 40 healthy volunteers as a control. Visual acuity testing, slit lamp examination and optical coherence tomography were performed on all patie...
Patients with non-segmental vitiligo had a considerably greater incidence of ocular alterations than controls, although there was no significant difference in visual acuity....
Vitiligo is a systemic condition that can affect the activity of melanocytes in organs besides the skin. The depigmentation process can influence ocular melanocytes. Ocular problems may be closely con...
Autoimmune atrophic gastritis (AAG) is rarely associated with coeliac disease (CD)....
To assess the frequency of AAG-CD association and to compare clinical, biochemical, and histological features of adults affected by both diseases (cases) with AAG controls....
This case-control study included 9 cases (F55%, median age 47, range 23-59yrs) matched (1:3) by age (±4 yrs) and gender to 27 controls randomly selected from our AAG cohort (2009-2021). The AAG and CD...
Of 434 AAG patients (median age:62.5yrs, range18-92yrs, F:M ratio=2.2:1),9 had a concomitant diagnosis of CD. The occurrence of AAG-CD association was 2% and 1.65% among AAG/CD cohorts, respectively. ...
AAG-CD association is rare. Gastric and duodenal biopsies might be advisable in young people with normocytic anaemia and associated autoimmune disorders to timely diagnose clinically silent conditions...
We explored the feasibility, suitability, and reliability of using controls recruited among members of a non-probabilistic online panel ('panel controls') in a case-control study (CCS) to investigate ...
We consider analyses of case-control studies assembled from electronic health records (EHRs) where the pool of cases is contaminated by patients who are ineligible for the study. These ineligible pati...
Nested case control (NCC) is a sampling method widely used for developing and evaluating risk models with expensive biomarkers on large prospective cohort studies. In a typical NCC design, biomarker v...
Endoscopic ultrasound-guided rendezvous (EUS-RV) is a recently added alternative salvage technique to percutaneous transhepatic cholangiography rendezvous (PTC-RV) for achieving biliary cannulation in...
A case-control study was conducted in the tertiary referral center, Ghent University Hospital. All consecutive patients that underwent a rendezvous procedure between February 2014 and March 2022 for f...
A total of 59 consecutive procedures in 57 patients were included for analysis; 20/59 (33.9%) were PTC-RV; the remaining 39/59 (66.1%) procedures were EUS-RV. Two patients in the PTC-RV group underwen...
EUS-RV has an acceptable success rate and is not associated with an increased risk of adverse events as compared to PTC-RV....
Lung cancer (LC) is one of the most critical neoplastic abnormalities, having globally a high mortality rate. Knowledge about its genetic mutations and their association with clinically pathological f...
To analyze the mutations of KRAS and BRAF in LC patients among Pakistani population....
The study has been carried out at universities and health institutes of Islamabad, Pakistan....
Deoxyribonucleic acid (DNA) was extracted from the patient samples by using the standard protocol and amplified by using the specific primers. Later on, the Polymerase Chain Reaction (PCR) products we...
Relationship between KRAS, BRAF mutations, and LC risk was accessed by conditional logistic regression using SPSS version 24.0. Results were illustrated by odds ratio (OR), 95% confidence interval (CI...
LC is more common in male population and smoking is one of the leading risk factors for (p < 0.0001) LC. KRAS and BRAF mutations were found to be contributing factors toward LC development and showed ...
It can be concluded that smoking is lethal and cancer causing. The concomitant mutations found in KRAS and BRAF were infrequent, and they probably have a very unusual effect on the clinical management...
Limited data are available regarding the risk factors for fistula-in-ano (FIA) in infants and toddlers, potentially affecting their daily lives....
The purpose of this study was to identify potential risk factors for FIA in infants and toddlers, in order to implement early preventive interventions, avoid disease progression, and develop therapeut...
A retrospective case-control study was conducted, comparing 41 infants and toddlers diagnosed with FIA with 41 healthy controls, between August 2020 and December 2021....
(a) maternal characteristics during pregnancy and delivery, (b) perinatal characteristics, dietary behaviors, and defecation-related behaviors in infants and toddlers, (c) family dietary behaviors....
Mothers of infants and toddlers with FIA had given birth more times in the past, while the infants and toddlers themselves had less mealtime, a higher rate of exclusive breastfeeding, frequent loose s...
Based on our data, it appeared that FIA in infants and toddlers could be attributed to several factors. These included an increased number of previous deliveries by mothers, frequent loose stools, and...
Recurrent urinary tract infections (rUTIs) affect 2-10% of adult women and are associated with a significant effect on quality of life, daily activities, and mental health....
The aim of this study was to identify clinical characteristics associated with rUTIs among women seeking care for pelvic floor disorders at an academic tertiary urogynecology clinic....
A retrospective case-control study of women presenting to an academic tertiary urogynecology clinic was conducted. Cases were women with rUTIs, defined as ≥2 UTIs in 6 months or ≥3 within 1 year. Cont...
A total of 285 cases with rUTIs were identified, and 150 matched controls had a mean (SD) age of 72 (11.8) years and a body mass index of 29.6 (6.7; calculated as weight in kilograms divided by height...
In this ambulatory urogynecologic population, prolapse through the introitus was negatively associated with rUTIs, whereas parity, increased medical comorbidities, and elevated postvoid residual volum...
Β2-microglobulin (β2-M) is associated with various malignancies. However, the relationship between β2-M and colorectal cancer (CRC) remains unclear. We explored the association between β2-M and CRC am...